Open Access<p>Fatty Acid Synthase (FASN) siRNA-Encapsulated-Her-2 Targeted Fab’-Immunoliposomes for Gene Silencing in Breast Cancer Cells</p>
Author(s) -
Arif Khan,
Ahmed N. Aljarbou,
Yousef H. Aldebasi,
Khaled S. Allemailem,
Mohammed A Alsahli,
Shamshir Khan,
Abdulmohsen M. Alruwetei,
Masood Alam Khan
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s256022
Subject(s) - gene silencing , fatty acid synthase , internalization , liposome , cancer cell , microbiology and biotechnology , viability assay , cell , cytotoxicity , chemistry , cell growth , cancer research , cell culture , cancer , biology , biochemistry , fatty acid , in vitro , gene , genetics
The overexpression of Her-2 in 25-30% breast cancer cases and the crosstalk between Her-2 and fatty acid synthase (FASN) establishes Her-2 as a promising target for site-directed delivery. The present study aimed to develop the novel lipid base formulations to target and inhibit the cellular proliferation of Her-2-expressing breast cancer cells through the silencing of FASN. In order to achieve this goal, we prepared DSPC/Chol and DOPE/CHEMS immunoliposomes, conjugated with the anti-Her-2 fab' and encapsulated FASN siRNA against breast cancer cells.